跳至主要内容
临床试验/NCT05099575
NCT05099575Unknown不适用

Different Protocols for Prevention of Atonic Postpartum Hemorrhage During Cesarean Delivery in High Risk Group

Assiut University0 个研究点目标入组 448 人开始时间: 2021年10月30日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
448
主要终点
Amount of blood loss

研究概览

简要总结

PPH is one of the most leading causes of maternal mortality,. It means loss of 500 ml blood after vaginal delivery and 1000 ml blood after cesarean delivery. Although it's preventable it represents about 27%of maternal deaths. Atony is the main cause of PPH. 70%of PPH corresponds to uterine atony. Uterotonics like oxytocin, misoprostol, ergometrine, carbetocin and combinations of these drugs can be used but until now there is no agreement on medication that can be the most effective.

研究设计

研究类型
Observational
观察模型
Case Crossover
时间视角
Cross Sectional

入排标准

年龄范围
19 Years 至 40 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Pregnant full term>37 w
  • Maternal age 19- 40 3.physical state 1&2 4.patient willing to enter the study

排除标准

  • 1.who refuse to participate in study 2.immunocomprmized and patients who had contraindicated from any of drugs used 3.patients with hypersensitivity to any drug

研究组 & 干预措施

Pregnant women who receive oxytocin

干预措施: Syntocinon, papal, misotac (Drug)

Pregnant Women who receive carbetocin

干预措施: Syntocinon, papal, misotac (Drug)

Pregnant women who receive misoprostol

干预措施: Syntocinon, papal, misotac (Drug)

Pregnant women who receive ergometrine

干预措施: Syntocinon, papal, misotac (Drug)

结局指标

主要结局

Amount of blood loss

时间窗: 1 year

Decrease amount of blood loss

次要结局

  • Finding the drug most effective with least adverse effects(1 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Randa Wanees Ahmed

Randa Wanees Ahmed

Assiut University

相似试验